| Similar Articles |
|---|
 |
Pharmaceutical Executive
April 1, 2007
Jill Wechsler |
Washington Report: Medicaid Sets the Pace for Pharma Pricing Forget Medicare price negotiations. Pending changes in Medicaid drug-pricing formulas will put even more pressure on pharmaceutical prices.   |
Managed Care
February 2007
Martin Sipkoff |
As Drug Payment Model Changes, Confusion Grows Among Insurers Purchasers are hopeful that life after "average wholesale price" will be simpler, fairer, and, with luck, easier to grasp. |
Pharmaceutical Executive
November 1, 2005
Patrick Clinton |
Are We Aligned Yet? A Medicare Part D Roundtable The most salient feature of the Medicare prescription drug benefit is its uncertainties. |
Pharmaceutical Executive
October 1, 2008
Chris Biddle |
Stop the Bleeding Pharmaceutical manufacturers overpay pharmacy benefit managers millions of dollars each year in rebate overpayments. Here's how to stop the leakage. |
Managed Care
January 2008
Thomas Kaye |
Now Is the Time for Pharmacy Performance Incentives We've made strides in increasing the transparency of pricing in the pharmacy supply chain, and now we need to change dispensing behavior. |
Pharmaceutical Executive
December 1, 2006
Rod Cavin |
Forecasting Medicare: Price Controls in the Years Ahead Part D in 2010 will be under price and access pressure. Pharma should develop plans for the future by imagining best- and worst-case scenarios. |
Managed Care
March 2008
Martin Sipkoff |
PBMs' Rebate Income Threatened By Lawsuits and Move to Generics A recent court settlement may affect the way the PBM industry makes profits, but could it also lead to higher drug costs? |
Pharmaceutical Executive
February 1, 2009
Jill Wechsler |
Securing Savings A close look at the healthcare industry will separate real cost-cutting measures from money-saving myths. |
Pharmaceutical Executive
September 1, 2006
Reznick & Kobak |
Legal: Authorized Generics: Still Legal--and Holding Despite the rattle and hum, courts continue to support the practice of authorized generics. The response? Generic manufacturers are changing the way they argue these cases. |
Managed Care
June 2003
Thomas Kaye |
Mail Order Pharmacy -- Savings or Added Cost? Mail order programs can provide savings, but HMOs need to ensure that they are actually receiving sufficient value. |
Pharmaceutical Executive
November 1, 2011 |
Does a German Launch Make Sense? Will the structure and ambiguity of Germany's new medicines pricing system bring a halt to new drug launches in Europe's largest market? |
Pharmaceutical Executive
August 1, 2013
Jill Wechsler |
Costs and Coverage Challenge Medicare Drug Plans Rate cuts and fraud concerns create problems for Part D plans and Part B providers. |
Managed Care
February 2006
Martin Sipkoff |
Don't Bet That Problems With Part D Are Over Medicare Part D enrollment snags could be just the start of political and regulatory headaches facing health plans and pharmacy benefit managers. |
BusinessWeek
May 10, 2004
John Carey |
Drug Prices: A New Covenant? The states' growing negotiating clout with Big Pharma raises crucial questions |
Pharmaceutical Executive
April 1, 2014 |
Whatever Happened To Faster Reimbursement For Generics In Europe? The plan to accelerate generic pricing and reimbursement has become another tragic European casualty. |
Pharmaceutical Executive
February 1, 2006
Jill Wechsler |
Washington Report: Cross-Agency Collaboration for Part D Medicare Part D gives CMS more clout over coverage, pricing, and even drug development. |
Pharmaceutical Executive
November 1, 2006
Patrick Clinton |
From the Editor: Under Revision Here is a closer look at a multi-jurisdiction case that charges 42 pharmaceutical companies with violating various RICO and deceptive-trade-practice acts by artificially inflating the Average Wholesale Price they reported to Medicare. |
Managed Care
January 2006 |
The Formulary Files The Pharmacy Benefit Management Institute reports an increase in drug margins. |
The Motley Fool
June 26, 2006
Stephen D. Simpson |
Is Novartis the Future of Generics? Merck's recent pricing action might just be the beginning of the end of generics as we know them. Investors, take note. |
Managed Care
December 2001 |
CMS Medicaid Managed Care Proposal Under Close Scrutiny Bioterrorism. Medicaid managed care plans. No link between them? Guess again. It all has to do with how proposed Medicaid regulations would affect patients' rights and funding for Medicaid programs ranging from nursing home care to emergency rooms... |
